Butenafine


Generic Medicine Info
Indications and Dosage
Topical/Cutaneous
Skin fungal infections
Adult: As 1% cream: Tinea corporis and tinea cruris: Apply to affected and surrounding area once daily for 2 weeks. Tinea pedis: Apply to affected skin between and around the toes bid for 1 week or once daily for 4 weeks. Tinea versicolor: Apply to affected and surrounding area once daily for 1-2 weeks.
Child: ≥12 years Same as adult dose.
Contraindications
Hypersensitivity to butenafine.
Special Precautions
Patient with allylamine antifungal (e.g. naftifine, terbinafine) hypersensitivity. Children. Pregnancy and lactation. Not intended to be used on nails, scalp, near mouth or eyes, or for vaginal yeast infections.
Adverse Reactions
Significant: Irritation, sensitivity.
Skin and subcutaneous tissue disorders: Burning or stinging sensation, itching, erythema. Rarely, contact dermatitis.
Patient Counseling Information
Avoid contact with eyes or other mucous membranes. Avoid occlusive dressings.
Monitoring Parameters
Perform culture and potassium hydroxide (KOH) examination. Assess for clinical signs of tinea pedis.
Action
Description:
Mechanism of Action: Butenafine, a synthetic benzylamine antifungal, exhibits its fungicidal activity by inhibiting squalene epoxidation thereby blocking ergosterol synthesis and subsequent weakening of fungal cell membranes.
Pharmacokinetics:
Absorption: Minimal systemic absorption. Time to peak serum concentration: 6-15 hours.
Metabolism: Metabolised in the liver via hydroxylation.
Excretion: Elimination half-life: Biphasic: 35 hours (α); >150 hours (β).
Chemical Structure

Chemical Structure Image
Butenafine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2484, Butenafine. https://pubchem.ncbi.nlm.nih.gov/compound/Butenafine. Accessed Oct. 24, 2023.

Storage
Store between 20-25°C. Storage recommendations may vary among individual products. Refer to specific product guidelines.
MIMS Class
Topical Antifungals & Antiparasites
ATC Classification
D01AE23 - butenafine ; Belongs to the class of other antifungals for topical use.
References
Anon. Butenafine Hydrochloride. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 26/04/2023.

Anon. Butenafine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 26/04/2023.

Buckingham R (ed). Butenafine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 26/04/2023.

Lotrimin Ultra Athletes Foot Cream (Bayer Healthcare LLC.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 26/04/2023.

Lotrimin Ultra Jock Itch Cream (Bayer Healthcare LLC.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 26/04/2023.

Mentax Cream (Mylan Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 26/04/2023.

Disclaimer: This information is independently developed by MIMS based on Butenafine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in